Literature DB >> 18236181

Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampinbased regimen.

Peter F M Choong1, Michelle M Dowsey, Derek Carr, John Daffy, Peter Stanley.   

Abstract

BACKGROUND AND
PURPOSE: Acute prosthetic infection is a serious problem. We report factors related to the incidence of acute infection and results of combined joint debridement and prolonged rifampicin-based antibiotic therapy. PATIENTS AND METHODS: Between 1998 and 2004, 14 acute infections occurred after 819 primary hip arthroplasties. The association between patient-related and surgical factors and the risk of infection were analyzed. Infections were treated with multiple joint lavage, debridement, 2 weeks of antibiotic therapy, and then oral antibiotics for a minimum of 6 months.
RESULTS: There was a correlation between having a body mass index (BMI) of >or=30, and also more than 2 co-morbidities, and an increased risk of infection. Diabetes was a potential risk factor. Following our regime of treatment, 11 of 14 patients retained their prosthesis. 2 of 3 who required resection arthroplasty underwent successful staged revision, while the third patient had no further surgery because of being deemed unfit.
INTERPRETATION: Primary joint replacement was salvaged in 11 of 14 patients. When successful re-implantation was included, 13 of 14 patients had a mobile prosthetic joint without further infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18236181     DOI: 10.1080/17453670710014527

Source DB:  PubMed          Journal:  Acta Orthop        ISSN: 1745-3674            Impact factor:   3.717


  47 in total

1.  Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.

Authors:  O C El Helou; E F Berbari; B D Lahr; J E Eckel-Passow; R R Razonable; I G Sia; A Virk; R C Walker; J M Steckelberg; W R Wilson; A D Hanssen; D R Osmon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-27       Impact factor: 3.267

2.  Meta-analysis shows that obesity may be a significant risk factor for prosthetic joint infections.

Authors:  Zhongxi Ma; Fengjin Guo; Jun Qi; Wei Xiang; Jinming Zhang
Journal:  Int Orthop       Date:  2015-08-15       Impact factor: 3.075

Review 3.  [Treatment of periprosthetic infections].

Authors:  L Renner; C Perka; A Trampuz; N Renz
Journal:  Chirurg       Date:  2016-10       Impact factor: 0.955

Review 4.  Treatment of acute periprosthetic infections with prosthesis retention: Review of current concepts.

Authors:  Jesse Wp Kuiper; Robin Tjeenk Willink; Dirk Jan F Moojen; Michel Pj van den Bekerom; Sascha Colen
Journal:  World J Orthop       Date:  2014-11-18

5.  Clinical Implication of Diabetes Mellitus in Primary Total Hip Arthroplasty.

Authors:  Young-Soo Chun; Seung-Hyuk Lee; Sang-Hoon Lee; Yoon-Je Cho; Kee Hyung Rhyu
Journal:  Hip Pelvis       Date:  2014-09-29

6.  Value of procalcitonin for diagnosing perioperative pneumonia, urinary infections and superficial surgical site infections in patients undergoing primary hip and knee arthroplasty.

Authors:  Lixuan Zhang; Daozhang Cai; Hanming Guo
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

7.  Sciatic nerve neuritis of no cause in primary total hip replacement: A case series.

Authors:  Chang Park; Adeel Ikram; Hani B Abdul-Jabar; Warwick J P Radford
Journal:  J Clin Orthop Trauma       Date:  2017-08-24

8.  Prosthetic joint infections.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 9.  Clinical practice. Infection associated with prosthetic joints.

Authors:  Jose L Del Pozo; Robin Patel
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

Review 10.  Can periprosthetic hip joint infections be successfully managed by debridement and prosthesis retention?

Authors:  Konstantinos Anagnostakos; Cornelia Schmitt
Journal:  World J Orthop       Date:  2014-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.